Luke Catherine J, Subbarao Kanta
Emerging Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 33, Room 3E13C.1, 33 North Drive, MSC 3203, Bethesda, MD 20892-3203, USA.
Expert Rev Vaccines. 2014 Jul;13(7):873-83. doi: 10.1586/14760584.2014.922416. Epub 2014 May 23.
A variety of platforms are being explored for the development of vaccines for pandemic influenza. Observations that traditional inactivated subvirion vaccines and live-attenuated vaccines against H5 and some H7 influenza viruses were poorly immunogenic spurred efforts to evaluate new approaches, including whole virus vaccines, higher doses of antigen, addition of adjuvants and combinations of different vaccine modalities in heterologous prime-boost regimens to potentiate immune responses. Results from clinical trials of prime-boost regimens have been very promising. Further studies are needed to determine optimal combinations of platforms, intervals between doses of vaccines and the logistics of deployment in pre-pandemic and early pandemic settings.
目前正在探索多种平台用于大流行性流感疫苗的研发。有观察发现，针对H5和某些H7流感病毒的传统灭活亚病毒颗粒疫苗和减毒活疫苗免疫原性较差，这促使人们努力评估新方法，包括全病毒疫苗、更高剂量的抗原、添加佐剂以及在异源初免-加强方案中采用不同疫苗形式的组合来增强免疫反应。初免-加强方案的临床试验结果非常有前景。还需要进一步研究以确定平台的最佳组合、疫苗剂量之间的间隔以及在大流行前和大流行早期环境中的部署后勤保障。
